期刊文献+

胰岛素鼻黏膜给药系统的研究进展

Progress of the intranasal administration of insulin
下载PDF
导出
摘要 目的综述胰岛素近年来鼻黏膜给药的相关信息。方法查阅国内外相关文献36篇,进行相关分析、归纳和总结。结果综述出鼻黏膜给药的特点以及提高鼻黏膜生物利用度的诸多方法。在胰岛素制剂中加入安全高效的吸收促进剂或水不溶性粉末将会很大程度上提高其生物利用度。结论胰岛素鼻黏膜给药在药学领域将会有广阔的发展前景。 Objective To review the new administration routes of insulin and the development of intranasal delivery system.Methods According to thirty-six recent relevant literatures,the new routes and the development of intranasal delivery system of insulin were summarized.The new routes of insulin administration,the characteristics of intranasal delivery and some strategies to improve the bioavailability of insulin after nasal administration were summarized.Results It seems that the addition of safe absorption enhancers or water-insoluble powders into insulin formulation can dramatically improve the bioavailability of insulin after nasal administration.Conclusions The intranasal administration of insulin in the pharmaceutical field is promising.
出处 《沈阳药科大学学报》 CAS CSCD 北大核心 2012年第4期312-319,共8页 Journal of Shenyang Pharmaceutical University
关键词 胰岛素 鼻黏膜给药 吸收促进剂 水不溶性粉末 insulin intranasal administration absorption enhancer water-insoluble powder
  • 相关文献

参考文献36

  • 1DUAN Xiao-pin,MAO Shi-rui.New strategies to im-prove the intranasal absorption of insulin[J].DrugDiscovery Today,2010,15(11-12):417-427. 被引量:1
  • 2李肖玲,安富荣,陆国红.胰岛素肺部给药系统研究进展[J].中国现代应用药学,2008,25(z1):609-613. 被引量:1
  • 3HENKIN R I.Inhaled insulin Intrapulmonary,in-tranasal,and other routes of administration:Mecha-nisms of action[J].Nutrition,2010,26(1):33-39. 被引量:1
  • 4毛世瑞,杨宏图,毕殿洲.提高药物鼻粘膜吸收的途径[J].中国药学杂志,1998,33(11):641-645. 被引量:15
  • 5梁文权.生物药剂学与药物动力学:第2版[M].北京:人民卫生出版社,2004:71-72. 被引量:1
  • 6SHECHTER Y,MIRONCHIK M,RUBINRAUT S,etal.Reversible pegylation of insulin facilitates its pro-longed action in vivo[J].European Journal of Pharma-ceutics and Biopharmaceutics,2008,70(1):19-28. 被引量:1
  • 7AGARWAL V,REDDY I K,KHAN M A.Polymethyac-rylate based microparticulates of insulin for oral deliv-ery:Preparation and in vitro dissolution stability in thepresence of enzyme inhibitors[J].International Journalof Pharmaceutics,2001,225(1-2):31-39. 被引量:1
  • 8SIMON M,WITTMAR M,KISSEL T,et al.Insulin con-taining nanocomplexes formed by self-assembly frombiodegradable amine-modified poly(vinyl alcohol)-graft-poly(L-lactide):bioavailability and nasal tolera-bility in rats[J].Pharmaceutical Research,2005,22(11):1879-1885. 被引量:1
  • 9ZHANG Xin-ge,ZHANG Hui-jie,WU Zhong-ming etal.Nasal absorption enhancement of insulin using PEG-grafted chitosan nanoparticles[J].European Journal ofPharmaceutics and Biopharmaceutics,2008,68(3):526-534. 被引量:1
  • 10MAO Shi-rui,GERMERSHAUS O,FISCHER D,et al.Uptake and transport of PEG-graft-trimethyl-chitosan-copolymer-insulin nanocomplexes by epithelial cells[J].Pharmaceutical Research,2005,22(12):2058-2068. 被引量:1

二级参考文献32

  • 1洪天配,杨金奎.2006年国际糖尿病联盟第19届世界糖尿病大会专题报道[J].中国糖尿病杂志,2007,15(1):62-64. 被引量:50
  • 2[23]BARNETT A H,DREYER M,LANGE P,et al.An open,randomized,parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjuctive therapy in patients with type 2 diabetes poorly controlled on metformin[J].Diabetes Care,2006,29(8):1818-1825. 被引量:1
  • 3[24]HOLLANDER P A,BLONDE L,ROWE R,et al.Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes:results of a 6-month,randomized,comparative trial[J].Diabetes Care,2004,27(10):2356-2362. 被引量:1
  • 4[25]HERMANSEN K,RONNEMAA T,PETERSEN AH,et al.Intensive therapy with inhaled insulin via the AERx insulin diabetes management system:a 12-week proof-of-concept trial in patients with type 2 diabetes[J].Diabetes Care,2004,27(1):162-167. 被引量:1
  • 5[26]HENRY R R,MUDALIAR S,CHU N,et al.Young and elderly type 2 diabetic patients inhaling insulin with the AERx insulin diabetes management system:a pharmacokinetic and pharmacodynamic comparison[J].J Clin Pharmacol,2003,43(11):1228-1234. 被引量:1
  • 6[27]HAUSMANN M,DELLWEG S,HEINEMANN L,et al.Add-on therapy with Kos inhaled insulin is as efficacious as add-on therapy with Lantus in poorly controlled type 2 diabetic patients treated with sulfonylureas or metformin[C].Program and abstracts of the European Association for the Study of Diabetes 41st Annual Meeting,2005; A817. 被引量:1
  • 7[28]TEETER J G,RIESE R J.Dissociation of lung function changes with humoral immunity during inhaled human insulin therapy[J].Am J Respir Crit Care Med,2006,173(11):1194-1200. 被引量:1
  • 8[29]SKYLER J,Exubera Phase II Study Group.Sustained long-term efficacy and safety of inhaled insulin during 4 years of continuous therapy[J].Diabetes,2004,53(Suppl 2):115. 被引量:1
  • 9[30]ROSENSTOCK J,ZINMAN B,MURPHY L F,et al.Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes[J].2005,143(8):549-558 被引量:1
  • 10[31]FINEBERG S E,KAWABATA T,FINCO-KENT D,et al.Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes.An analysis of initial phase II and III inhaled insulin(Exubera) trials and a two-year extension trial[J].J Clin Endocrinol Metab,2005,90(6):3287-3294. 被引量:1

共引文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部